Norris Medicines
Norris Medicines Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Norris Medicines
Start SIPNorris Medicines Investment Rating
-
Master Rating:
-
Norris Medicines has an operating revenue of Rs. 7.88 Cr. on a trailing 12-month basis. An annual revenue de-growth of -12% needs improvement, Pre-tax margin of -14% needs improvement, NULL From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 3 | 1 | 1 | 3 | 3 | 1 | 1 |
| Operating Expenses Qtr Cr | 3 | 1 | 1 | 3 | 3 | 1 | 1 |
| Operating Profit Qtr Cr | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Tax Qtr Cr | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Net Profit Qtr Cr | 0 | -1 | -1 | 0 | -1 | 0 | -2 |
Norris Medicines Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 13
- Bearish Moving Average
- ___
- 3
- 20 Day
- ₹12.23
- 50 Day
- ₹11.91
- 100 Day
- ₹11.85
- 200 Day
- ₹12.00
- 20 Day
- ₹12.04
- 50 Day
- ₹11.76
- 100 Day
- ₹11.78
- 200 Day
- ₹11.87
Norris Medicines Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 13.04 |
| Second Resistance | 13.26 |
| Third Resistance | 13.53 |
| RSI | 58.56 |
| MFI | 85.49 |
| MACD Single Line | 0.24 |
| MACD | 0.37 |
| Support | |
|---|---|
| First Resistance | 12.55 |
| Second Resistance | 12.28 |
| Third Resistance | 12.06 |
Norris Medicines Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 1,243 | 68,800 | 55.35 |
| Week | 1,894 | 124,793 | 65.88 |
| 1 Month | 1,906 | 144,620 | 75.88 |
| 6 Month | 1,783 | 138,134 | 77.49 |
Norris Medicines Result Highlights
Norris Medicines Synopsis
| Market Cap | |
| Sales | |
| Shares in Float | |
| No of funds | |
| Yield |
| Book Value | |
| U/D Vol ratio | |
| LTDebt / Equity | |
| Alpha | |
| Beta |
Norris Medicines
| Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
|---|---|---|---|---|
| Promoters | 34.01% | 34.01% | 34.04% | 34.04% |
| Mutual Funds | 0.01% | 0.01% | 0.01% | 0.01% |
| Financial Institutions/ Banks | 0.06% | 0.06% | 0.06% | 0.06% |
| Individual Investors | 20.66% | 20.62% | 20.55% | 20.59% |
| Others | 45.26% | 45.3% | 45.34% | 45.3% |
Norris Medicines Management
| Name | Designation |
|---|---|
| Mr. Vimal Shah | Managing Director |
| Mrs. Susmita Mahapatra | Woman Director |
| Dr. Hiten Parikh | Director |
| Mr. Shaikh Amanullah Mohamed Azmathullah | Director |
Norris Medicines Forecast
Price Estimates
Norris Medicines Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-11-18 | A.G.M. | |
| 2023-11-10 | Quarterly Results | |
| 2023-08-10 | Quarterly Results | |
| 2023-05-25 | Audited Results | |
| 2023-02-13 | Quarterly Results |
Norris Medicines FAQs
What is Share Price of Norris Medicines ?
Norris Medicines share price is ₹12 As on 02 December, 2023 | 07:15
What is the Market Cap of Norris Medicines ?
The Market Cap of Norris Medicines is ₹12.5 Cr As on 02 December, 2023 | 07:15
What is the P/E ratio of Norris Medicines ?
The P/E ratio of Norris Medicines is -6.8 As on 02 December, 2023 | 07:15
What is the PB ratio of Norris Medicines ?
The PB ratio of Norris Medicines is -1 As on 02 December, 2023 | 07:15